Risk stratification model for diabetic kidney disease progression based on metabolic and inflammatory biomarkers

doi:10.4239/wjd.121173

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

(15)

(12)

(0)

(1)

(127)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Aug 15, 2026; 17(8): 121173
Published online Aug 15, 2026. doi: 10.4239/wjd.121173

Table 4 Comparison with established risk prediction models

Model	Derivation C-index	Validation C-index	Calibration slope	NRI
Our nomogram	0.843 (0.807-0.879)	0.826 (0.779-0.873)	0.96	Reference
KFRE	0.781 (0.738-0.824)	0.768 (0.716-0.820)	0.89	23.6%
KDIGO model	0.765 (0.721-0.809)	0.752 (0.698-0.806)	0.87	26.8%
CKD Progression score	0.748 (0.703-0.793)	0.735 (0.680-0.790)	0.84	29.3%

Values are presented with 95%CIs where applicable. All comparisons with our nomogram: P < 0.05. KFRE: Kidney Failure Risk Equation; KDIGO: Kidney Disease: Improving Global Outcomes; NRI: Net reclassification improvement; CKD: Chronic kidney disease.

Full Size Table

Citation: Du N, Li WX, Qiu CY, Wang J. Risk stratification model for diabetic kidney disease progression based on metabolic and inflammatory biomarkers. World J Diabetes 2026; 17(8): 121173
URL: https://www.wjgnet.com/1948-9358/full/v17/i8/121173.htm
DOI: https://dx.doi.org/10.4239/wjd.121173